7 July 2021 top three startups: FabricNano, Hertility Health, Antheia
RapidPulse Raises $15M in Series A Funding
RapidPulse, a Miami FL-based medical device company developing an aspiration system to treat ischemic stroke, raised $15M in Series A funding.
The round was led by Santé Ventures with participation from Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon.
The company plans to use the funds to advance its system through expanded clinical evaluation and build out its platform of proprietary catheters.
Led by Sean McBrayer, CEO, RapidPulse is developing a novel aspiration system to treat ischemic stroke. The RapidPulse™ Cyclic Aspiration System includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain.
RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry.
RapidPulse Raises $15M in Series A Funding | FinSMEs
RapidPulse, a Miami FL-based medical device company developing an aspiration system to treat ischemic stroke, raised $15M in Series A funding
DrChrono Raises $12M in Funding
DrChrono, a Sunnyvale CA-based company focused on platform and services for modern medical practices, raised $12M in funding.
The round was led by ORIX Growth Capital.
The company intends to use the funds to expand the telehealth offerings on the DrChrono platform, grow operations and enhance across the other key product areas including EHR, practice management, medical billing and its core partner API.DrChrono provides a platform which offers EHR, practice management, medical billing, revenue cycle management, and API solutions. It is currently used by thousands of physicians and has over 28 million patients under the care of DrChrono providers. The company has facilitated millions of appointments and the processing of more than $11 billion of medical billing to date.
DrChrono Raises $12M in Funding | FinSMEs
DrChrono, a Sunnyvale CA-based company focused on platform and services for modern medical practices, raised $12M in funding
Nigerian e-health startup MDaaS Global raises $2.3m to launch new solution, expand across country
Founded in 2017 by Oluwasoga Oni, Opeyemi Ologun, Genevieve Barnard Oni, and Joseph McCord, MDaaS Global is building and operating a network of modern, tech-enabled diagnostic centres across Nigeria.
Through its patient-facing brand BeaconHealth Diagnostics, the startup offers a wide range of services including imaging services such as digital x-ray and ultrasound, cardiac services such as ECG and echo, and lab services, ranging from chemistry analysis and immunoassay to hematology.
So far MDaaS Global has launched seven centres in Ibadan, Ilorin, Osogbo, Lagos and Abuja, and provided diagnostic services to over 40,000 patients in underserved communities. The company has also performed over 80,000 diagnostics tests across cardiology, radiology, neurology, laboratory, and general health checks.
It has now raised a US$2.3 million seed extension round led by Newtown Partners via the Imperial Venture Fund, with participation from CRI Foundation, FINCA Ventures, Techstars, and Future Africa, among others.
With the funding, MDaaS Global is launching SentinelX, a digital health membership that champions preventive, personalised, and continuous care using proprietary technology. Currently in private beta and with a speedily growing waitlist, SentinelX is set to launch publicly in September 2021.
Nigerian e-health startup MDaaS Global raises $2.3m to launch new solution, expand across country - Disrupt Africa
Nigerian e-health startup MDaas Global has raised a US$2.3 million seed extension funding round to help it launch a new service - SentinelX - and expand across the country.
Osmind Closes $15M Series A Funding Round
Osmind, a San Francisco, CA-based healthcare technology company building a digital infrastructure for neuropsychiatry, raised $15m in Series A funding.
The round was led by Future Ventures, with participation from existing investor General Catalyst and new investors Tiger Global, Offline Ventures, and Yahoo! co-founder Jerry Yang’s AME Cloud Ventures, as well as angels Joshua Kushner (co-founder of Oscar Health and Thrive Capital), Adrian Aoun (founder of Forward), Jonathan Hirsch (founder of Syapse), Alice Zhang (co-founder of Verge Genomics), Bay Gross (co-founder of Cityblock Health), and Linhao Zhang (co-founder of TrialSpark).
The company, which also announced the addition of Miki Kapoor (co-founder of Verana Health) as an advisor, intends to use the funds to further develop and expand its electronic health record (EHR) and research platform, to make key hires and to expand its research collaborations.
Led by Lucia Huang, CEO, Osmind is building an operating system for neuropsychiatry to enable clinicians and researchers to bring mental health treatments to patients. Its EHR software solution is used by progressive mental health providers to track outcomes, streamline workflows, and increase client engagement for evidence-based practices. It allows clinicians to track measurement-based outcomes for intensive treatment modalities and deliver more tailored care, automates compliance processes for the U.S. FDA and insurance companies, and streamlines patient and practice management. The software also aggregates de-identified real-world data to accelerate research and development of new mental health treatments and diagnostics such as psychedelic medicines, neuromodulation, digital therapeutics, digital phenotyping, and neuroimaging.
Osmind Closes $15M Series A Funding Round | FinSMEs
Osmind, a San Francisco, CA-based healthcare technology company building a digital infrastructure for neuropsychiatry, raised $15m in Series A funding
British biotech startup FabricNano raises $12.5M in Atomico-led round, also backed by Biz Stone and Emma Watson
Recently, British biotech startup FabricNano has raised $12.5M (approx €10.5M) funding in a Series A round led by Atomico.
Other investors including, Backed, Hoxton Ventures, Entrepreneur First, and several angels like Biz Stone (Twitter co-founder), Emma Watson (UN Sustainability Ambassador), Arvind Gupta (Indiebio founder and Mayfield partner), Alexander Moscho (former CEO Bayer), Michael Stoppelman (former Yelp SVP Engineering), Elvie founder Tania Boler, and Vijay Pandurangan (former Twitter NY engineering site lead), also participated.
Based out of London, FabricNano is a cell-free biomanufacturing company that aims to replace all fermented and petrochemical products with biomanufactured alternatives like bioplastics, biofuels, and other common commodity chemicals, globally. The advancement in cell-free synthetic biology is enabling inventions in sustainable biomanufacturing. In actuality, it is emerging as an alternative to microbial fermentation, which suffers from various restrictions. Cell-free biomanufacturing is a budding technology sector, which has several new entrants that are all solving a number of interesting problems.
British biotech startup FabricNano raises $12.5M in Atomico-led round, also backed by Biz Stone and Emma Watson | Silicon Canals
FabricNano is a cell-free biomanufacturing company that aims to replace all fermented and petrochemical products with biomanufactured alternatives raises $12.5M
Hertility Health Raises £4.2M in Seed Funding
Hertility Health, a UK-based new women’s health startup, closed a £4.2m seed funding round.
The round was led by LocalGlobe, Venrex, and some key angel investors including former CEO of Bupa, Evelyn Bourke, CEO of Nested and the unicorn company GoCardless, Matt Robinson.
The company intends to use the funds to expand its current product offering of fertility and hormone testing, menopause, miscarriage, postnatal care, polycyctic ovarian syndrome (PCOS) and endometriosis testing, aid the expansion of its current clinical trials which aim to reduce the diagnosis time for some of the most common reproductive conditions, and establish it as a scientific and clinical educational health hub for women.
Led by Dr. Natalie Getreu – COO, Dr. Helen O’Neill – CEO, and Deirdre O’Neill – CCO, Hertility Health is a science-driven network of care created to give reproductive and hormone health the attention it needs. The company offers not just a test, but a triage system, and their services connect women with licensed experts and clinics, providing them with a personalised care pathway. Results are then published onto a personalised online dashboard, offering insights into ovarian reserve, menstrual cycle and ovulation, hormone health and highlights any fertility red flags.
Hertility Health Raises £4.2M in Seed Funding
Hertility Health, a UK-based new women’s health startup, closed a £4.2m seed funding round
Element Biosciences Raises $276M in Series C Financing
Element Biosciences, a San Diego, CA-based developer of a DNA sequencing platform, closed a $276m Series C financing.
Backers included new investors Janus Henderson Investors, Logos Capital, Meritech Capital Partners, Counterpoint Global (Morgan Stanley), and T. Rowe Price and existing investors Fidelity Management & Research Company, Foresite Capital, JS Capital Management LLC, RA Capital Advisors, and Venrock.
The company, which has raised approximately $400m in total funding, intends to use the capital to scale the commercial organization in anticipation of, as well as fund, the launch of its next-generation sequencing solution.
Led by Molly He, Ph.D., co-founder and chief executive officer, and John Stuelpnagel, DVM, chairman, Element Biosciences is a multi-disciplinary life science company currently focused on developing DNA sequencing technology for research and diagnostic markets, acceleration of scientific discoveries and broadening of the use of genomic medicine.
Element Biosciences Raises $276M in Series C Financing
Element Biosciences, a San Diego, CA-based developer of a DNA sequencing platform, closed a $276m Series C financing
SWORD Health closes on $85 million Series C for virtual MSK care
SWORD Health, a virtual musculoskeletal care platform founded in 2015, announced today that it has raised an $85 million Series C funding round led by General Catalyst.
Other participating investors included BOND, Highmark Ventures, BPEA, Khosla Ventures, Founders Fund, Transformation Capital, and Green Innovations. The funding comes months after the company raised a $25 million Series B round – which, put differently, means that the New York-based company has now raised $110 million across six months.
SWORD Health connects consumers to a virtual physical therapist who is accessible via traditional telemedicine. Beyond that, the company gives each consumer a tablet and motion sensors. The consumers are promoted to go through the motions, and get feedback and tips through a SWORD Health Digital Therapist.
SWORD Health closes on $85 million Series C for virtual MSK care – OrthoFeed
(TechCrunch) – SWORD Health, a virtual musculoskeletal care platform founded in 2015, announced today that it has raised an $85 million Series C funding round led by General Catalyst.
Antheia Raises $73M in Series B Funding
Antheia, a Menlo Parck CA-based synthetic biology company, raised $73M in Series B funding.
The round was led by Viking Global Investors with participation from Sherpalo Ventures and Hillspire.
The company intends to use the funds to expand its pipeline and scale production in global markets.
Led by Dr. Christina Smolke, cofounder and CEO, Antheia is a synthetic biology company enabling next-generation plant-inspired medicines through a novel whole-cell engineering approach to reconstruct complex molecules in yeast. The funds will support the company to bring its first pharmaceutical compound to market and scale up the production of a number of active pharmaceutical ingredients (APIs) and key starting materials (KSMs).
Antheia Raises $73M in Series B Funding | FinSMEs
Antheia, a Menlo Parck CA-based synthetic biology company, raised $73M in Series B funding
Adela Raises $60M in Series A Funding
Adela (formerly DNAMx), a Toronto, Canada-based company which specializes in detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test, raised $60M in Series A funding.
The round was led by F-Prime Capital with participation from OrbiMed, Deerfield Management, Decheng Capital and RA Capital Management.
The company plans to to use the advance its technology towards commercialization, with initial applications across the cancer care continuum from early detection to disease monitoring. In the future, the company plans to apply the technology to other disease states, leveraging the genome-wide approach to enable expansion to other conditions.
Led by Scott Bratman, MD, PhD, Chief Executive Officer, and Daniel De Carvalho, PhD, Chief Scientific Officer, Adela has the mission to enable the detection of cancer and other high-morbidity, high-mortality conditions through a blood test that harnesses the potential of the methylome. The company’s genome-wide methylation enrichment technology offers the potential to detect many diseases with a single assay at scale, with best-in-class performance.
Adela Raises $60M in Series A Funding
Adela (formerly DNAMx), a Toronto, Canada-based company which specializes in detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test, raised $60M in Series A funding
Tendo Systems Raises $50M in Series B Funding
Tendo Systems, a Philadelphia PA-based provider of healthcare management software, raised $50M in Series B funding.
The round, which brought Tendo’s valuation to $550m, was led by Lux Capital, with participation from General Catalyst.
The company, which has raised $69m to date, intends to use the funds to accelerate its plans to expand its software, connecting patients, clinicians, and caregivers throughout the care journey.
Started by siblings Dan and Jen Goldsmith, Tendo Systems provides a digital engagement platform and suite of applications that connect patients, clinicians, and caregivers throughout the care cycle.
Tendo Systems Raises $50M in Series B Funding | FinSMEs
Tendo Systems, a Philadelphia PA-based provider of healthcare management software, raised $50M in Series B funding
Babson Diagnostics Raises $31M in Series B Funding
Babson Diagnostics, an Austin TX-based medical technology company, raised $31M in Series B funding.
The round was led by Emerald Development Managers with participation from Healthineers, Prism Ventures, and Lago Consulting Group.
The company intends to use the funds to expand its laboratory and ecosystem infrastructure, finalize its blood testing solution development, and grow its sales and marketing teams. In conjunction with the funding, Neil Cohen, founder and chairman of Emerald Development Managers, will join Babson’s board of directors.
Originally incubated at Siemens Healthineers and using an innovative collection device developed in collaboration with BD (Becton, Dickinson and Company), Babson has advanced a technological ecosystem that reimagines the entire diagnostic blood testing process. Innovations in collection, sample handling, and analysis enable the company to use small capillary samples to produce a full range of diagnostic test.
Led by and David Stein, Ph.D., chief executive officer, Eric Olson, Babson’s founder, chairman, and chief operating officer, Babson plans to deploy its proprietary diagnostics ecosystem at pharmacies and other retail locations throughout the country.
Babson Diagnostics Raises $31M in Series B Funding | FinSMEs
Babson Diagnostics, an Austin TX-based medical technology company, raised $31M in Series B funding
ObvioHealth Raises $31M in Funding
ObvioHealth, a NYC-based global Virtual Research Organization (VRO), raised $31m in funding.
The round was led by new investors Dedalus Group, an international healthcare IT and diagnostic software provider, and Novotech Health Holdings Pte. Ltd., Asia Pacific’s biotech-specialist CRO.
The company intends to use the funds to boost the IT capabilities of its proprietary ecosystem and platform for conducting virtual clinical trials, including the GDPR compliant bridging software to query EHR data, and make key hires in the coming year, particularly in Asia, with plans to expand the Singapore office into a technology hub.
Led by Ivan Jarry, CEO, ObvioHealth is an end-to-end Virtual Research Organization (VRO) that delivers data to sponsors and a clinical trial experience for participants. The company developed and launched one of the first DCT apps, downloadable on smartphones enabling people to participate in clinical trials from home. In the 4 years since launch, the company has been awarded nearly 40 studies from 28 blue chip clients, implemented in 28 countries, in 16 different therapeutic areas.
ObvioHealth Raises $31M in Funding
ObvioHealth, a NYC-based global Virtual Research Organization (VRO), raised $31m in funding
Syllable Raises $28M in Series B Funding
Syllable, a Sunnyvale, Calif.-based an AI-powered healthcare services company, raised $28m in Series B funding.
The round was led by Oak HC/FT with participation from Section 32. In conjunction with the funding, Vig Chandramouli, Principal at Oak HC/FT, will join the Syllable Board of Directors.
The company intends to use the funds to scale partnerships with health systems, deploy with payers, and grow the team.
Led by Kobus Jooste, CEO, Syllable has built an AI platform that answers every call received by a hospital and enables automated workflows and self-service options to help patients find and take the correct next step in their healthcare journey. The platform introduces patients to an agent for situations that require a human touch for successful call resolution.
Syllable Raises $28M in Series B Funding | FinSMEs
Syllable, a Sunnyvale, Calif.-based an AI-powered healthcare services company, raised $28m in Series B funding
Apton Biosystems Raises $24M in Series A Financing
Apton Biosystems, Inc., a Pleasanton, CA-based developer of Super-Res sequencing and single-molecule detection systems for large-scale clinical applications, such as early cancer detection and population sequencing, closed a $24m Series A financing.
The round was led by Kern Capital with participation by new and existing investors including Casdin Capital and Khosla Ventures. Concurrent with the financing, Jay Kern of Kern Capital has joined Apton’s board of directors.
The company intends to use the funds to continue developing its Super-Res sequencing and single-molecule proteomics detection systems.
Led by John Hanna, CEO, Apton Biosystems is a developer of Super-Res™ sequencing and single-molecule detection systems for large-scale clinical applications such as early cancer detection and population sequencing. Its Super-Res™ technology sequences tens of billions of reads in a single run using simple, un-patterned flow cells that lower variable costs.
